[Value of urinary markers in the diagnosis and follow-up of urothelial bladder tumours].
Urothelial bladder tumours require regular surveillance: cystoscopy associated with urine cytology are reference examinations. Several new markers currently under evaluation or already validated have recently been proposed to replace cytology and potentially reduce or even replace unnecessary cystoscopies. The biological fluid studied for all of these markers is the same as that of urine cytology, i.e. urine. The authors review the results of recent studies on these new urinary markers. The results of these markers demonstrate a better global sensitivity than urine cytology, but often a lower specificity. In the majority of cases, these tests are performed during patient follow-up (NMP22, BTA, CYFRA 21-l., etc.), but do not replace cystoscopy, due to a large number of false-positives. Other techniques, such as FISH, uCyt+ or microsatellites appear to be more promising, especially for the diagnosis of low-grade tumours. The best solution in practice may consist of a combination of several markers to further improve sensitivity and to decrease the false-positive rate responsible for unnecessary cystoscopies.
Campos-Fernandes
Jean-Louis
JL
Service d'Urologie, Centre Hospitalier Lyon-Sud, Lyon, Pierre Bénite, France. jeanlouiscf@yahoo.fr
Descotes
Françoise
F
André
Jean
J
Perrin
Paul
P
Devonec
Marian
M
Ruffion
Alain
A
D014408:Biomarkers, Tumor / Q000652:urine*; D005500:Follow-Up Studies; D006801:Humans; D009687:Nuclear Proteins / Q000652:urine; D019098:Telomerase / Q000652:urine; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000652:urine*
D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22; D019098:Telomerase